Evidence-Based Products

Take Control
STUDY CLAIM: Sixty-two patients with hypercholesterolaemia who ate 25g/day Take Control for eight weeks had a 10-15 per cent drop in LDL cholesterol levels.

PUBLISHED: Neil HAW. Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis 2001;156:329-37.

ABSTRACT: In a randomised, double-blind, controlled crossover trial with two consecutive eight-week periods, researchers studied 30 patients with heterozygous familial hypercholesterolaemia treated concurrently with an HMG-CoA reductase inhibitor (statin) and 32 patients with type IIa primary hypercholesterolaemia with a total cholesterol concentration >6.5mmol/L not taking lipid-lowering drug therapy.

The active treatment was 25g/day Take Control providing 2.5g plant sterols. After four weeks, LDL cholesterol levels decreased by 0.04mmol/L in the placebo group and ­0.76mmol/L in the active treatment group. After eight weeks, the corresponding results were 0.0mmol/L and ­0.51mmol/L. HDL cholesterol and triglyceride concentrations did not change.

Researchers concluded that Take Control can reduce LDL cholesterol levels by 10­15 per cent with no difference in hypercholesterolaemic patients taking statin drugs and those not taking lipid-lowering drug therapy.

POTENTIAL APPLICATIONS: Take Control is a vegetable oil sterol-enriched fat spread.

Unilever Bestfoods
800 Sylvan Ave., Englewood Cliffs, New Jersey 07632
Tel: +1 201 894 7387

STUDY CLAIM: Juven, a mixture of 3g beta-hydroxy-beta-methylbutyrate, 14g L-glutamine and 14g L-arginine, may help Acquired Immunodeficiency Syndrome (AIDS) patients increase body weight, predominantly in lean body mass.

PUBLISHED: Clark R, et al. Nutritional treatment for AIDS-associated wasting using beta-hydroxy-beta-methylbutyrate, glutamine and arginine: a randomised, double-blind, placebo-controlled study. J Parenter Enteral Nutr 2000;24(3):133-9.

ABSTRACT: Researchers studied a combination of beta-hydroxy-beta-methylbutyrate (HMB), a metabolite of leucine, L-glutamine and L-arginine, each of which has been shown to slow muscle proteolysis, to determine if they could synergistically slow muscle wasting in AIDS patients.

They recruited 68 HIV-infected patients with at least 5 per cent weight loss in the previous three months. Patients received either placebo or Juven (1.5g HMB, 7g L-glutamine and 7g L-arginine) twice/day for eight weeks.

Forty-three patients completed the protocol and those taking Juven gained 3 +/- .5kg body weight, whereas the placebo group gained .37 +/- .84 kg. Immune status, muscle mass and fat mass also improved in the treatment group.

POTENTIAL APPLICATIONS: Juven, in orange- and grape-flavoured drink powder is designed for people experiencing muscle mass loss and/or wasting associated with cancer and AIDS.

MTI BioTech Inc.
2625 North Loop Dr., Suite 2150
Ames, Iowa 50010
Tel: +1 877 465 8836

STUDY CLAIM: Potassium hydrogen D-glucarate may be a natural, nontoxic colon cancer inhibitor.

PUBLISHED: Yoshimi N, et al. Inhibition of azoxymethane-induced rat colon carcinogenesis by potassium hydrogen D-glucarate. Int J Oncol 2000 Jan;16(1):43-8.

ABSTRACT: While calcium D-glucarate was shown to inhibit chemical carcinogenesis in various animal models, the effect of potassium hydrogen D-glucarate has not been extensively investigated.

In this study, potassium hydrogen D-glucarate (PHG) (Preventium) markedly inhibited azoxymethane (AOM)-induced colon carcinogenesis in male F344 rats. Researchers gave 140mmol/kg PHG or potassium hydrogen carbonate (PHC) to rats in their diet.

Continual postinitiation treatment with PHG reduced tumor incidence and multiplicity at 60 per cent of the animal's life expectancy. PHC had no effect. Amelioration of over-expression of the betaG gene in rat colon carcinomas was observed using RT-PCR and Northern blot analysis. Researchers hypothesized that previously demonstrated conversion of PHG to D-glucaro-1, 4-lactone, a potent inhibitor of beta-glucuronidase (betaG), may be responsible for this effect.

The mechanism of PHG inhibition of colon carcinogenesis may also involve suppression of cell proliferation and possibly alterations in cholesterol synthesis or cholesterol metabolism of bile acids.

Researchers concluded that PHG has potential as a natural, nontoxic inhibitor of colon cancer.

POTENTIAL APPLICATIONS: Preventium is available as a raw ingredient for dietary supplements for people at risk for colon cancer.

Applied Food Sciences
Capitol of Texas Hwy., Bldg. 3, Suite 205
Austin, Texas 78746
Tel: +1 512-306-9580
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.